Modality
ADC
MOA
FXIai
Target
TROP-2
Pathway
Notch
PompeCholangiocarcinomaRCC
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ Dec 2029
Phase 1Current
NCT07203169
873 pts·RCC
2025-06→TBD·Active
NCT06663954
1,679 pts·Cholangiocarcinoma
2021-08→2029-12·Active
2,552 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-127mo awayConference· Pompe
2029-12-223.7y awayPh2 Data· Cholangiocarcinoma
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
P1/2
Active
Catalysts
Conference
2026-11-12 · 7mo away
Pompe
Ph2 Data
2029-12-22 · 3.7y away
Cholangiocarcinoma
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07203169 | Phase 1/2 | RCC | Active | 873 | Mayo |
| NCT06663954 | Phase 1/2 | Cholangiocarcinoma | Active | 1679 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |